Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
There are two primary aims in the study: 1) to determine the tolerability and feasibility of
combination hypofractionated radiation therapy and PD-1 inhibition with nivolumab, and 2) to
determine the ability of hypofractionated radiation therapy to enhance response rate from
PD-1 inhibition versus PD-1 inhibition alone by comparing the observed response rate under
the combination therapy with a previously reported response rate under inhibition alone.